CHEMOTHERAPY INTENSIFICATION THROUGH INTERVAL COMPRESSION IN EWING'S SARCOMA

通过间隔压缩对尤文氏肉瘤进行强化化疗

• 批准号: 7607505
• 负责人: YOUSIF H MATLOUB
• 金额: $ 0.01万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607505
• 关键词: Chemotherapy-Oncologic Procedure; Clinical Trials; Combination Chemotherapy; Computer Retrieval of Information on Scientific Projects Database; Databases; Drug usage; Ewings sarcoma; Funding; Grant; Infusion procedures; Institution; National Cancer Institute; Operative Surgical Procedures; Patients; Phase III Clinical Trials; Physician Data Query; Primitive Neuroectodermal Tumor; Radiation therapy; Randomized; Recruitment Activity; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Week; Work; chemotherapy; compare effectiveness; day; neoplastic cell; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting patients. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. This is a randomized Phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor. Patients will be randomly assigned to one of two groups. Patients in Group 1 will receive infusions of combination chemotherapy on 2-5 days every 3 weeks for up to four courses. Patients in Group 2 will receive infusions of combination chemotherapy on 2-5 days every 2 weeks for up to six courses. Beginning in Week 13, some patients in both groups will undergo surgery to remove the tumor followed by chemotherapy with or without radiation therapy. Other patients will either undergo radiation therapy before surgery followed by additional radiation therapy plus chemotherapy or undergo radiation therapy alone plus chemotherapy. Patients will be evaluated every 3 months for 4 years and every 6 months for 1 year.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究不再招募患者。 （临床试验总结来自国家癌症研究所的PDQ数据库） 化疗中使用的药物以不同的方式阻止肿瘤细胞分裂，使它们停止生长或死亡。放射治疗使用高能x射线来破坏肿瘤细胞。目前尚不清楚哪种化疗方案联合放射治疗和/或手术治疗尤文肉瘤或原始神经外胚层肿瘤更有效。 这是一项随机III期试验，旨在比较不同化疗方案联合放疗和/或手术治疗尤文肉瘤或原始神经外胚层肿瘤患者的有效性。 患者将被随机分配至两组之一。 第1组患者将接受联合化疗，每3周输注2-5天，最多4个疗程。第2组患者将接受联合化疗，每2周输注2-5天，最多6个疗程。 从第13周开始，两组中的一些患者将接受手术切除肿瘤，然后进行化疗，伴或不伴放射治疗。其他患者将在手术前接受放射治疗，然后接受额外的放射治疗加化疗，或接受单独的放射治疗加化疗。患者将每3个月接受一次评价，持续4年，每6个月接受一次评价，持续1年。